Oxford Immunotec Global (NASDAQ:OXFD) Upgraded at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Oxford Immunotec Global (NASDAQ:OXFD) from a strong sell rating to a sell rating in a report released on Saturday, BidAskClub reports.

OXFD has been the topic of a number of other reports. ValuEngine cut Oxford Immunotec Global from a hold rating to a sell rating in a research note on Tuesday, July 23rd. TheStreet cut Oxford Immunotec Global from a c- rating to a d+ rating in a research note on Monday, July 15th. Finally, Zacks Investment Research cut Oxford Immunotec Global from a buy rating to a hold rating in a research note on Thursday, August 1st. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and one has issued a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus price target of $18.00.

OXFD opened at $12.84 on Friday. Oxford Immunotec Global has a one year low of $11.88 and a one year high of $19.19. The firm has a market capitalization of $351.69 million, a PE ratio of 25.18 and a beta of 0.33. The firm has a 50 day simple moving average of $13.43. The company has a quick ratio of 12.03, a current ratio of 12.60 and a debt-to-equity ratio of 0.04.

Oxford Immunotec Global (NASDAQ:OXFD) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.14. Oxford Immunotec Global had a return on equity of 13.56% and a net margin of 172.27%. The firm had revenue of $14.79 million for the quarter, compared to analysts’ expectations of $13.74 million. During the same period in the prior year, the firm posted ($0.40) earnings per share. The firm’s quarterly revenue was up 26.6% on a year-over-year basis. As a group, equities analysts predict that Oxford Immunotec Global will post -0.24 earnings per share for the current year.

In other Oxford Immunotec Global news, Director Richard A. Sandberg sold 3,000 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $19.90, for a total transaction of $59,700.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 4.21% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. FIL Ltd acquired a new stake in shares of Oxford Immunotec Global in the first quarter valued at $5,586,000. Northern Trust Corp raised its stake in shares of Oxford Immunotec Global by 0.7% in the fourth quarter. Northern Trust Corp now owns 290,723 shares of the company’s stock valued at $3,715,000 after acquiring an additional 2,113 shares in the last quarter. Martingale Asset Management L P raised its stake in shares of Oxford Immunotec Global by 41.2% in the first quarter. Martingale Asset Management L P now owns 165,512 shares of the company’s stock valued at $2,853,000 after acquiring an additional 48,300 shares in the last quarter. Millennium Management LLC raised its stake in shares of Oxford Immunotec Global by 117.2% in the fourth quarter. Millennium Management LLC now owns 117,914 shares of the company’s stock valued at $1,507,000 after acquiring an additional 63,617 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Oxford Immunotec Global by 15.9% in the fourth quarter. Geode Capital Management LLC now owns 101,930 shares of the company’s stock valued at $1,302,000 after acquiring an additional 13,974 shares in the last quarter. Institutional investors and hedge funds own 91.19% of the company’s stock.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

Further Reading: Earnings Per Share

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

MSA Safety Inc  Declares Quarterly Dividend of $0.42
MSA Safety Inc Declares Quarterly Dividend of $0.42
Pioneer Floating Rate Trust  Announces Monthly Dividend of $0.06
Pioneer Floating Rate Trust Announces Monthly Dividend of $0.06
Pioneer High Income Trust  Declares $0.07 Monthly Dividend
Pioneer High Income Trust Declares $0.07 Monthly Dividend
Conestoga Capital Advisors LLC Increases Stock Position in Core Laboratories
Conestoga Capital Advisors LLC Increases Stock Position in Core Laboratories
Pioneer Municipal High Income Trust  Declares Monthly Dividend of $0.05
Pioneer Municipal High Income Trust Declares Monthly Dividend of $0.05
Alaska Air Group, Inc.  Declares Quarterly Dividend of $0.35
Alaska Air Group, Inc. Declares Quarterly Dividend of $0.35


© 2006-2019 Ticker Report